Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Government launches £200m life sciences investment programme

The government has launched a £200 million life sciences investment programme to support innovation in the sector.

The 10-year strategy includes seven healthcare missions focused on the early prevention, diagnosis, monitoring and treatment of disease. It will also aim to accelerate the development and adoption of new drugs, diagnostics, medical technology and digital tools for a wide array of diseases -- building on successes of Covid-19 response and accelerate delivery of innovations to patients.


The vision outlines seven "critical" healthcare missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. They include:

  • Accelerating the pace of studies into novel dementia treatment
  • Enabling early diagnosis and treatments, including immune therapies such as cancer vaccines
  • Sustaining the UK’s position in vaccine discovery, development and manufacturing
  • Treatment and prevention of cardiovascular diseases and its major risk factors, including obesity
  • Reducing mortality and morbidity from respiratory disease in the UK and globally
  • Addressing the underlying biology of ageing
  • Increasing the understanding of mental health conditions, including work to redefine diseases and develop tools to address them

Commenting on the vision, Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said: “This is an ambitious statement about how the UK can become a life sciences superpower.

“We’ve seen just how important the partnership between industry, the government and the NHS has been to the response to the pandemic, and we need to take the same approach if we are going to make the UK a global hub for life sciences.

“By putting the NHS at the centre of the vision, we can also deliver for patients and make the UK the best place in the world to research, develop, manufacture, and use the latest medicines and vaccines.”

While the vision aims to cultivate a "business environment" which would benefit the UK life sciences companies, by enabling access to finance for innovation and growth, a key sector of generic manufacturers feel slighted.

BGMA astonished at being sidelined

Mark Samuels, chief executive of the British Generic Manufacturers Association (BGMA) flagged concerns about the government’s vision for life sciences.

He said: “A key theme from the government’s vision for life sciences is that it addresses and supports the diversity of the sector yet it entirely ignores our industry which ultimately supplies four out of five NHS medicines.

Mark Samuels BGMA Mark Samuels, CEO of the British Generic Manufacturers Association

“I find it astonishing that we are both relied upon as a critical element of medicines supply yet side-lined and taken for granted when it comes to these forward-looking funding initiatives.

"Of course it is critical to invest across the life sciences sector -- particularly in light of what has been achieved via the Covid-19 vaccines -- but the pandemic has also taught us that innovation is not just to be found in new and untried areas.

"The first medicine approved to effectively treat patients suffering with Covid-19 was a repurposed generic in Dexamethasone. We believe there are scores of existing generic medicines which -  with just a fraction of the funding talked about in the OLS (off of the life sciences) vision - could be used to treat unmet patient need.

“We also have grave concerns that the vision also places more work and onus on the MHRA (Medicines and Healthcare products Regulatory Agency) at a time when it is also facing significant budget cuts which will ultimately impact patient access to medicines.”

More For You

Henry Gregg, new Chief Executive of the National Pharmacy Association.
Henry Gregg
Henry Gregg

Community pharmacy voices need to be ‘heard really loud’, new NPA chief tells Pharmacy Business

Henry Gregg, the new chief executive of the National Pharmacy Association (NPA), believes community pharmacies have a right to have insight into discussions relating to the pharmacy funding contract.

Currently, Community Pharmacy England (CPE) solely negotiates the elements of the Community Pharmacy Contractual Framework (CPCF) with the Department of Health and Social Care (DHSC) and NHS England.

Keep ReadingShow less
Patient care

The NHS said the benefits were "too small to justify the additional cost"

NHS rejects Alzheimer's drugs shown to delay early-stage of disease

Two new treatments for Alzheimer's disease will not be offered on the NHS due to high costs and "too small" benefits.

Donanemab and Lecanemab have been hailed as breakthrough treatments for slowing down the symptoms of early-stage Alzheimer's, the most common type of dementia.

Keep ReadingShow less
Air pollution in UK linked to thousands of deaths and chronic health conditions

A report by the Royal College of Physicians claims that air pollution was causing harm to almost every organ of the body.

iStock

Royal College of Physicians paints grim picture of air pollution in UK

Doctors warn that around 99 per cent of the population in the UK are breathing "toxic air", and around 30,000 deaths will be linked to air pollution in 2025.

The Royal College of Physicians (RCP) claimed in a report that air pollution was causing harm to almost every organ of the body, and shortening life by 1.8 years on average.

Keep ReadingShow less
Community pharmacies falling behind on data security toolkit submissions

The last date for submission is 30 June 2025.

Pic credit: iStock

Community pharmacies falling behind on data security toolkit submissions

More than 50 per cent of the community pharmacies in England have failed to complete their Data Security and Protection Toolkit 2025 with the deadline in less than two weeks.

Necessary guidance regarding the toolkit has previously been provided by Community Pharmacy England (CPE) earlier.

Keep ReadingShow less
Digital guide launched to help patients with osteoporosis

In the UK, over three million people have osteoporosis.

Pic credit: iStock

Digital guide launched to help patients with osteoporosis

The Royal Osteoporosis Society (ROS) has launched a free online service called BoneMed which is aimed to support patients with osteoporosis in taking their medicine and remove barriers to adherence.

After completing a five-minute online survey, patients will be emailed a summary of the medicine they have been prescribed and six further updates throughout the year on their medication.

Keep ReadingShow less